Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms

NCT04797767 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04797767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04797767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 4, 2022
Completion date
December 31, 2028
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute biphenotypic leukemia, acute myeloid leukemia, mixed phenotype acute leukemia, myeloid neoplasm, recurrent myeloid sarcoma, refractory acute biphenotypic leukemia, refractory acute myeloid leukemia, refractory mixed phenotype acute leukemia, refractory myeloid neoplasm, relapsed acute biphenotypic leukemia, relapsed acute myeloid leukemia, relapsed mixed phenotype acute leukemia, relapsed myeloid neoplasm